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Abstract
Complement factor H (FH), an elongated and substantially glycosylated 20-domain protein, is a
soluble regulator of the complement alternative pathway (AP). It contains several glycan binding
sites which mediate recognition of α2-3-linked sialic acid (FH domain 20) and glycosaminoglycans
(domains 6–8 and 19–20). FH also binds the complement C3-activation product C3b, a powerful
opsonin and focal point for the formation of C3-convertases of the AP feedback loop. In freely cir-
culating FH the C3b binding site in domains 19–20 is occluded, a phenomenon that is not fully
understood and could be mediated by an intramolecular interaction between FH’s intrinsic sialy-
lated glycosylation and its own sialic acid binding site. In order to assess this possibility, we char-
acterized FH’s sialylation with respect to glycosidic linkage type and searched for further potential,
not yet characterized sialic acid binding sites in FH and its seven-domain spanning splice variant
and fellow complement regulator FH like-1 (FHL-1). We also probed FH binding to the sialic acid
variant Neu5Gc which is not expressed in humans but on heterologous erythrocytes that restrict
the human AP and in FH transgenic mice. We find that FH contains mostly α2-6-linked sialic acid,
making an intramolecular interaction with its α2-3-sialic acid specific binding site and an asso-
ciated self-lock mechanism unlikely, substantiate that there is only a single sialic acid binding site
in FH and none in FHL-1, and demonstrate direct binding of FH to the nonhuman sialic acid
Neu5Gc, supporting the use of FH transgenic mouse models for studies of complement-related
diseases.
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Introduction
Complement factor H (FH), a serum protein composed of 20 ellips-
oid complement control protein repeats (CCPs) that are connected
head-to-tail, is a negative regulator of the complement alternative
pathway (AP), a branch of innate immunity that requires active
down-regulation. FH contains eight N-glycosylation sites, each car-
rying single- to multiantennae sialoglycans, adding almost 18 kDa to
its mass (Fenaille et al. 2007). Its regulatory action targets the com-
plement component C3-activation product C3b, the central protein
of a positive feedback loop in which all complement pathways con-
verge. FH accelerates the decay of the AP C3 convertase (C3bBb)
and serves as a co-factor to the serine protease factor I (FI) that
degrades C3b (Xue et al. 2017). FH-mediated down-regulation of
C3b activity is targeted to host tissue to which FH localizes via one
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or both of its two host glycan recognition sites, located in CCPs 6–8
and CCPs 19–20. These domains engage host-specific glycans,
namely glycosaminoglycans (GAGs, CCPs 6–8 and CCPs 19–20) or
sialic acid (Sia)-containing glycans (CCP 20). Both GAG sites prefer
the heparan sulfate (HS)/heparin type over other GAG types but dif-
fer in their relative affinities for differentially (de-)sulfated forms of
heparin (Clark et al. 2013). FH also binds sialylated glycans (Fearon
1978; Pangburn and Müller-Eberhard 1978; Michalek et al. 1988a),
likely simultaneously with surface-bound C3b (Wu et al. 2009;
Kajander et al. 2011; Morgan et al. 2011; Blaum et al. 2015). In full
length FH the two binding sites for C3b (located in CCPs 1–4 and
19–20) are not equally accessible (Schmidt et al. 2013; Herbert et al.
2015). Instead, free FH adopts one or several conformation(s) in
which the C-terminal C3b binding site is obscured (DiScipio 1992;
Oppermann et al. 2006; Schmidt et al. 2010; Makou et al. 2012;
Herbert et al. 2015; Baud et al. 2016). The structural basis for the
FH conformational heterogeneity or for a possible regulatory mech-
anism that could adjust the equilibrium between conformations with
accessible and obscured C-terminal C3b binding sites is unknown.
One possibility could be a self-locking mechanism in which the FH
sialylated glycan chains interact with the FH sialic acid binding site
in domain 20.
In our past structural analysis of Sia recognition by FH (Blaum
et al. 2015), we focused on the previously established Sia binding
site in FH’s most C-terminal domain CCP 20 and the most common
Sia variant in humans, α-N-acetylneuraminic acid (αNeu5Ac). We
found that FH binds α2-3- but not α2-6- or α2-8-linked Neu5Ac, in
agreement with functional investigations by other groups (Michalek
et al. 1988b; Ram et al. 1998; Gulati et al. 2005; Hyvärinen et al.
2016). We now characterized the glycosidic linkage types present in
the eight FH glycan chains. We further probed for the existence of
additional, not yet characterized Neu5Ac binding sites in FH and its
N-terminal splice variant FH-like 1 (FHL-1) (Schwaeble et al. 1987;
Ripoche et al. 1988) to exclude that potential Sia-recognition by
FHL-1, which is the main complement regulator on Bruch’s mem-
brane, is implicated in the pathophysiology of age-related macular
degeneration (AMD) (Clark et al. 2014). We also wanted to
cross-validate the common approach of investigating (human) FH
functions in FH transgenic mice models as well as on heterologous
erythrocytes, which traditionally serve in complement activity assays
(e.g., sheep erythrocytes). To this end we probed direct binding of
FH to α-N-glycolylneuraminic acid (αNeu5Gc), a common mamma-
lian Sia variant that is not expressed in humans but in the FH trans-
genic mice model and on the surface of heterologous erythrocytes.
Results
The glycan recognition site in FH CCPs 6–8 does not
contribute to Sia-mediated erythrocyte protection
from complement attack by FH
Sheep erythrocytes (RBCs) are non-activators of the human AP and
are stable in normal human serum (NHS) supplemented with Mg-
EGTA (which preserves activity of the AP but not the classical or
mannose-binding lectin complement pathways). Hemolysis can be
induced by neuraminidase treatment or by addition of recombinant
FH CCPs 19–20 (FH19–20), which necessarily requires the presence
of RBC sialylation in order to compete FH and induce lysis
(Schmidt et al. 2013; Hyvärinen et al. 2016). The current model for
these observations is direct competition of FH19–20 with serum FH
for simultaneous binding of plasma-membrane Sia and small
amounts of cell-bound C3b (Ferreira et al. 2006).
We employed this assay to assess the possibility that FH CCPs 6–8,
which contain one of the two FH GAG binding sites, also bind to
plasma membrane sialoglycans. To this end, we prepared washed
sheep RBCs in NHS supplemented with Mg-EDTA and added
recombinant FH6–8 (both the Y402 and H402 variant that is linked
to AMD) or recombinant FH19–20 (for comparison). Even at a con-
centration of 10 μM FH6–8 virtually no hemolysis was observed,
Fig. 1. The glycan recognition site in FH CCPs 6–8 does not compete for erythrocyte binding by FH. Sheep erythrocytes were prepared in normal human serum
supplemented with Mg-EDTA and incubated with varying amounts of recombinant FH fragments (white bars: FH19–20, light gray bars: FH6–8 402Y, dark gray
bars: FH6–8 402H). Hemolysis was quantified via absorbance at 415 nm and is given as percentage relative to hemolysis in distilled water. Average values of
four independent assays with SD are shown.
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whereas 2.5 μM of FH19-20 induced well over 50% of hemolysis
(where 100% equals complete osmotic hemolysis with distilled
water) (Figure 1). This observation suggests that recombinant FH6–8,
unlike FH19–20, does not compete with serum FH for Sia binding on
sheep RBCs and hence that FH CCPs 6–8 do not contribute to Sia
recognition by FH.
Neither FH6–8 nor FHL-1 bind directly to sialylated
glycans
Because of the so-called AP “tick-over”, which constantly produces
a small amount of C3-convertase and thus deposits C3b in a rather
unselective manner, the hemolytic assay may assess FH’s capacity to
simultaneously bind to Sia and cell-bound C3b rather than to Sia
alone (Ferreira et al. 2006). While FH19–20 also contains a C3b
binding site directly adjacent to the Sia binding site in CCP 20
(Blaum et al. 2015, 2016), it is not entirely clear if FH6–8 also
engages C3b. A potential binding site in FH CCPs 6–8 for C3b was
reported but the binding affinity was too low for an accurate deter-
mination (Schmidt et al. 2008). Thus, to complement the hemolytic
assay with FH6–8 by an experiment that is entirely independent of
FH’s interaction with C3 activation fragments, we conducted satur-
ation transfer difference (STD) NMR experiments with two
recombinant FH6–8 variants (Y402 and H402) and sialylated gly-
can representatives of the three glycosidic linkage types that are
most commonly observed in human sialoglycans (i.e., with α2-3-,
α2-6-, or α2-8-linked Neu5Ac caps, respectively). We also included
FHL-1 and a FH construct containing CCP 13 (for which a potential
carbohydrate recognition site has been proposed but could not be
confirmed (Pangburn et al. 1991; Ormsby et al. 2006; Schmidt et al.
2008)) in the STD NMR experiments. Unlike FH and FH19–20,
none of the other shortened FH constructs (FH6–8Y, FH6–8H
and FH8–15) nor FHL–1 bound to any of the three soluble sialy-
lated glycans (3′sialyllactose (3′SL), 6′sialyllactose (6′SL), and the
GD3 glycan) (Figure 2A). Together with the hemolytic assay these
experiments confirm the Sia binding site in CCP 20 as the only Sia
binding site in FH and suggest that FHL-1 does not bind to Sia
in vitro.
FH binds the nonhuman Sia variant Neu5Gc
Using STD NMR experiments, we analyzed whether serum-derived FH
recognizes Neu5Gc, which is not expressed in humans but in other
mammals, including sheep and mice (Chou et al. 1998; Hedlund et al.
2007). First, we used the monosaccharide 2-O-methyl-α-N-glycolyl-
neuraminic acid (Neu5GcαOMe, 2-O-methylated in order to prevent
Fig. 2. FHL-1 and recombinant fragments of FH devoid of CCPs 19–20 do not bind to sialylated glycans. Representatives of α2-3, α2-6, and α2-8-linked Neu5Ac
(3’SL, 6’SL, and the GD3 glycan, respectively, chemical structures shown with Neu5Ac glycosidic linkage types in red) were measured at 2mM each and STD
NMR experiments were recorded at 283 K in PBS containing D2O instead of H2O with different proteins at around 10 μM present. Spectra from top to bottom:
proton 1D reference spectrum of the sugar mix (top), STD NMR difference spectra with FH (second from top), with FH8-15 (third from top), with FH6–8 402Y
(fourth from top), with FHL-1 (fifth from top), and, for comparison, without protein (bottom). Proteins used are shown schematically with naturally occurring gly-
cosylation sites highlighted as “Y”. All recombinantly produced proteins (i.e., all apart from FH) were deglycosylated with Endo Hf during the purification pro-
cedure. The FHL-1 C-terminus (deviation from FH sequence) is spelled out as amino acid sequence. The STD NMR difference spectrum with FH is the only STD
spectrum with noticeable magnetization transfer to one of the three sialoglycans (signals belong to 3’SL proton resonances).
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mutarotation and formation of the non-physiological β-anomer) but
did not observe any interaction with FH (Figure 3). However, with a
larger Neu5Gcα-containing glycan, namely the trisaccharide
Neu5Gcα2-3Galβ1-4Glcβ-propyl-N3 (glycolyl-3′SL-ProN3), good mag-
netization transfer from FH and from FH19–20 was detected
(Figure 3). This experiment, together with indirect evidence from bio-
chemical studies (Gulati et al. 2005), demonstrates that nonhuman
Neu5Gc is recognized by human FH just as well as Neu5Ac. Our
observation that a single Sia ring (i.e., Neu5GcαOMe) is not capable of
FH binding is in agreement with our previous crystallographic and
NMR spectroscopic analysis, which showed that further pyranoses
attached to the specifically recognized Sia ring (for example in sialy-
lated trisaccharides such as 3′SL) entertain so-called CH–π interactions
with the W1183 side chain in FH and also receive substantial magnet-
ization transfer in STD NMR experiments (Blaum et al. 2015, 2016).
For glycolyl-3′SL-N3 such transfer of magnetization to the non-Sia
rings Gal and Glc (but, notably, not to the non-physiological propargyl
linker) is also observed (Figure 3), suggesting that Neu5Gc-capped
glycans are bound by FH in much the same manner as Neu5Ac-
capped glycans.
FH is primarily α2-6-sialylated
The FH sequence contains nine theoretical N-glycosylation sites, eight
of which are in fact glycosylated (Fenaille et al. 2007). Glycosylation
is restricted to domains 9 to 18. The most common non-reducing
end oligosaccharide sequences of human complex N-glycans are
Neu5Acα2-3Galβ1-4GlcNAc and Neu5Acα2-6Galβ1-4GlcNAc.
We have previously shown that FH specifically binds to trisaccharides
which terminate in the Neu5Acα2-3Gal disaccharide (Blaum et al.
2015). Thus, FH’s own glycosylation may resemble the sialylated
host markers on which it relies for self-recognition purposes. In
order to clarify in how far FH itself is α2-3- or α2-6-sialylated, we
undertook mass spectrometry-based characterization of the indi-
vidual glycosidic linkage types. We employed a chemical modifi-
cation strategy with which α2-6-linked Neu5Ac is ethyl esterified
while the α2-3-linked variant is lactonized, introducing a mass
difference between both Sia types and achieving charge neutral-
ization and sialic acid stabilization at the same time (Reiding
et al. 2014). The glycans were enzymatically released, derivatized,
and subsequently analyzed using matrix-assisted laser desorption/
ionization time-of-flight tandem mass spectrometry (MALDI-TOF-MS).
We identified 15 different glycan compositions in FH from human
serum, with the A2S2 type (two-antennary disialylated) being the
most abundant type by far (79.5% ± 0.1%). In total, 74.8% ± 0.3%
of the FH glycans are diantennary with both Sia caps in the α2-6 link-
age variant. Only 4.7% ± 0.2% of the diantennary glycans have
a single α2-3-linked Sia cap, and no diantennary glycans with two
α2-3-linked Sia caps are observed (Figure 4 and Table I). The
total percentage of α2-6 and α2-3 linked Sia, with respect to the
total level of sialylation and taking mixed species into account,
was found to be 91.5% and 8.5%, respectively. Consistent with
the absence of O-glycosylation, treatment with a deglycosylation
mix containing PNGase F and O-glycosidase did not reduce the
apparent molecular weight of FH (as observed by SDS-PAGE) fur-
ther than treatment with PNGase F only (data not shown).
Fig. 3. FH binds the nonhuman Neu5Gc variant of sialic acid. From top: Proton 1D reference spectrum of Neu5Gcα2-3Galβ1-4Glcβ-propyl-N3 (glycolyl-3’SL-
ProN3, chemical structure shown; Neu5Gc differs only by one additional OH-group in the acetyl side chain from the Neu5Ac Sia-variant in 3’SL); STD NMR dif-
ference spectrum of 2mM glycolyl-3’SL-ProN3 with 8 μM of FH; STD NMR difference spectrum of 2mM glycolyl-3’SL-ProN3 with 50 μM of FH19–20; Proton 1D
reference spectrum of Neu5GcαOMe; STD NMR difference spectrum of 2mM Neu5GcαOMe with 8 μM of FH. The structures of FH and FH19–20 are shown sche-
matically with glycosylation sites highlighted as “Y”. Magnetization transfer from the Neu5Gc-trisaccharide is observed for all three pyranose rings but not for
the propyl linker protons (resonances at 1.7 ppm and 3.25 ppm), while no transfer is observed for the monosaccharide (bottom spectrum).
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Discussion
Carbohydrate recognition by FH is linked via genetic disposition to
tissue-specific complement-mediated diseases, in particular AMD (on
Bruch’s membrane) and atypical hemolytic uremic syndrome (aHUS, in
the kidney glomerulus) (Carroll and Sim 2011; Kavanagh et al. 2013).
Due to the low affinities with which oligosaccharides bind to FH
in vitro and the chemical complexity of mammalian glycosylation a
comprehensive understanding of the role that glycans play in AP
Fig. 4. FH itself is primarily α2-6-sialylated. MALDI-TOF-MS spectrum and structural assignment of glycans released from FH. Mostly disialylated diantennary
(A2S2 and A2S2F) but also trisialylated triantennary (A3S3 and A3S3F) and traces of monosialylated diantennary glycans (A2S1 and A2S1F) are observed. The
chemical composition, including the Sia glycosidic linkage type(s) of each species, is depicted schematically. Linkage types were assigned based on mass differ-
ences that were introduced via chemical derivatization prior to MALDI-TOF-MS analysis.
Table I. Relative abundances of ethyl esterified glycans compared to HPCE-LIF analyzed APTS derived glycansa
Ethyl esterified N-glycansa Mean (±SD) Mean (±SD) Relative proportiona APTS derived N-glycansb
H5N4E1 3.8 (0.28) 3.8 (0.28) 9.2 A2S1
H5N4F1L1 1.0 (0.06) 1.3 (0.09) 2.0 A2S1F
H5N4F1E1 0.3 (0.03)
H5N4E1L1 4.7 (0.16) 79.5 (0.10) 67.4 A2S2
H5N4E2 74.8 (0.26)
H5N4F1L2 2.3 (0.06) 4.7 (0.03) 8.9 A2S2F
H5N4F1E1L1 1.4 (0.02)
H5N4F1E2 1.0 (0.01)
H6N5E2L1 4.2 (0.15) 7.0 (0.18) 3.9 A3S3
H6N5E3 2.8 (0.04)
H6N5F1E2L1 2.0 (0.07) 2.0 (0.07) 4.0 A3S3F




“H” represents hexose, “N” N-acetyl hexosamine, “F” fucose, “E” ethylated N-acetyl neuraminic acid and finally “L” represents lactonized N-acetyl neur-
aminic acid. aReiding et al. (2014); bFenaille et al. (2007).
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regulation is still lacking. It is, however, certain that both types of FH
self-markers (i.e., HS-proteoglycans and sialylated glycans) are not
functionally redundant with respect to their interaction with FH.
Instead, it seems that both glycan types act as tissue-specific self-mar-
kers to FH, i.e. proteoglycans appear to be the dominant self-markers
in Bruch’s membrane and sialylated glycans in the glomerulus (possibly
with additional contribution by proteoglycans whose GAG chains are
structurally distinct from those on Bruch’s membrane) (Clark et al.
2013; Blaum et al. 2015; Langford-Smith et al. 2015). Our finding that
FHL-1, the main AP regulator on Bruch’s membrane, and FH CCPs
6–8, previously shown to bind stronger to Bruch’s membrane than FH
CCPs 19–20, do not bind to sialylated oligosaccharides further sup-
ports the hypothesis that GAGs act as the major or sole self-markers in
Bruch’s membrane (Clark et al. 2013). It is, however, possible that
recruitment of FH by Sia plays a role in complement protection in
other parts of the eye where full length FH may be present, for example
in the retinal interphotoreceptor matrix for which a prevalence of α2-
3-linked Neu5Ac was previously suggested on the basis of lectin bind-
ing experiments (Bishop et al. 1993).
Like many serum proteins, FH itself is heavily glycosylated, and
it is possible that the intrinsic glycosylation plays a direct or indirect
role in FH’s activity – including the reported conformational
heterogeneity of FH, which impacts C3b binding. A comparison of
N-glycosylation consensus sequence sites across different mamma-
lian FH sequences, which could give hints as to which glycan chains
are functionally important, shows that the N-glycosylation sites in
FH are not subject to strict conservation but nevertheless tend to
cluster in certain regions, namely those that are not directly impli-
cated in ligand binding. Most glycosylation sites are located between
CCPs 12 and 15, in CCP 17 and 18, and in the linker region
between CCPs 8 and 9 (Supplementary data, Figure S1). Thus far,
none of these regions have been convincingly implicated in direct
interactions with FH’s principal ligands. A possible interpretation of
this observation is that the glycan chains in FH serve predominantly
indirect purposes, such as solubility or resistance to proteolytic deg-
radation. In order to experimentally evaluate if the FH glycan chains
may directly mediate a back-bending mechanism in which the FH
Sia binding site in CCP 20 would bind to its own glycan chains and
modulate accessibility of the C-terminal C3b binding site, we char-
acterized the FH glycan chains with respect to the Neu5Ac glyco-
sidic linkage types and demonstrate that the vast majority of
glycan chains in pooled serum-derived FH is decorated with α2-6-
linked Neu5Ac. This finding is in line with a reported excess of α2-
6-over α2-3-linked Neu5Ac in pooled human plasma proteins
(Gagneux et al. 2003; Reiding et al. 2014). Because FH itself has a
clear preference for binding α2-3-linked Sia (Blaum et al. 2015;
Hyvärinen et al. 2016) this finding makes a scenario in which the
FH Sia binding site interacts with its own glycan chains (or those
of other FH molecules) unlikely. Since sialylation levels and
Sia-linkage types change with age and disease, such a regulatory
mechanism would also be highly unlikely from a theoretical point
of view as FH conformational equilibria would otherwise shift
with age (Garcia et al. 2005; Pousset 1997). Of note, desialylation
and further deglycosylation of plasma-purified FH with bacterial
neuraminidase and fungal endo-N-acetyl-glucosaminidase did not
decrease the protein’s ability to decay cell-bound AP C3-convertase
nor its ability to distinguish between activators and non-activators
of the AP (Jouvin et al. 1984). The same is true for full-length FH
produced in Pichia pastoris and subsequently deglycosylated with
Endo Hf (Schmidt et al. 2011). Together, these observations sug-
gest that the glycan chains are not critical for FH’s structural
architecture – although they could still influence the protein’s con-
formational dynamics.
The sialic acid family consists of more than 50 different α-keto
sugars. Most of these differ from the prevalent Sia type in humans,
the nine-carbon pyranose αNeu5Ac, through additional acetyl and/
or hydroxyl groups (Varki et al. 2017). Absolute and relative
expression levels of individual Sia variants are species- and tissues
specific, with the Neu5Ac and Neu5Gc being the overall most com-
mon mammalian variants. Humans lost the ability to hydroxylate
Neu5Ac to yield Neu5Gc but can incorporate Neu5Gc directly from
dietary sources (Tangvoranuntakul et al. 2003; Ng et al. 2014;
Springer et al. 2014). Sheep RBCs, on the other hand, contain
Neu5Gc (Klimas et al. 1982). The observation that sheep RBCs are
non-activators of the human AP, therefore, hints to a certain promis-
cuity of human FH with respect to this nonhuman Sia variant.
Notably, wild type mice and thus human FH transgenic mouse mod-
els that are used to study complement diseases express Neu5Gc in
multiple organs including the kidney, making the question if
human FH binds Neu5Gc highly relevant for the interpretation of
data obtained with these animal models (Hedlund et al. 2007;
Pickering et al. 2007). From a structural point of view, the Sia
binding site in FH CCP 20 should be able to accommodate an
additional hydroxyl group positioned at the Neu5Ac acetyl func-
tion, i.e., Neu5Gc (Blaum et al. 2015), and our STD NMR experi-
ment with a Neu5Gc-containing trisaccharide confirms this
assumption. Potential physiological benefits of FH’s incapacity to
discriminate between Neu5Ac and nonhuman Neu5Gc, however,
remain enigmatic. Presentation of Sia and related nonulosonate
sugars on microbial lipooligosaccharide (LOS) is an AP evasion
strategy (Ram et al. 1998). For Neisseria gonorrhoeae (Ng) the
specificity of glycosylation-mediated serum resistance is well
documented and it was shown that both Neu5Ac- and Neu5Gc-
modification of Ng LOS convey human AP-resistance (Gulati
et al. 2015). However, in a physiological setting Ng scavenges
CMP-activated sugars for LOS-decoration from its host, and
humans provide only traces of CMP-Neu5Gc (possibly from diet-
ary intake). Therefore, no evolutionary disadvantages appear
associated with the lack of discrimination between the two Sia
types by FH. Nevertheless, the finding that FH directly binds to
Neu5Gc-containing glycans has medical implications as human
FH transgenic mice (which produce Neu5Gc) are used as animal
models for infection with serum-resistant Ng strains and
complement-specific diseases such as aHUS (Pickering et al. 2007;
Gulati et al. 2015). Since both Ng serum resistance and aHUS
predisposition are linked to FH-Sia recognition (Blaum et al.
2015; Gulati et al. 2015; Hyvärinen et al. 2016) such animal
models would be highly questionable if FH was not promiscuous
with respect to Neu5Ac hydroxylation.
In the context of Neu5Gc we would like to note that the aHUS-
linked FH variant S1191L/V1197A, which reflects also the only
sequence difference between the C-terminal domains of FH and its
antagonist FH related-1 (FHR-1), may (unlike FH) bind weaker to
Neu5Gc- than to Neu5Ac-containing glycans because the 1191L
side chain may interfere with the additional hydroxyl group (for
crystallographic images of the binding site including the S1191 side
chain see (Blaum et al. 2015)). It was, however, already shown that
the double mutation impairs FH19–20 binding also to human ery-
throcytes (Ferreira et al. 2009). A reason could be steric hindrance
by the larger Leu side chain in position 1191 (which is close to the
Neu5Ac methyl group in the complex) or reduced hydrophobic con-
tacts between the smaller Ala side chain at position 1197 and the
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Sia glycerol chain (Blaum et al. 2015). It was proposed that the
S1191L/V1197A double mutation could alter sialic acid specificity
(de Jorge et al. 2018). We do not think this likely (with the excep-
tion of Neu5Gc) since the mutations are both well away from the
Sia glycosidic linkage and the preceding pyranoses in the crystal
structure of the complex. It is, however, possible that the conform-
ational dynamics of the hypervariable loop (FH residues
1182–1189) are affected by the mutations. Since the double mutant
reduces C3b binding by FH19–20 (Ferreira et al. 2009), and since
C3b binding may promote the open, Sia-binding conformation of
this loop (Blaum 2017) altered structural dynamics in this region of
mutated FH and FHR-1 could also be the reason for impaired Sia
binding by FHR-1.
Materials and methods
Proteins, recombinant production and purification
In terms of full length FH, a commercial source (CompTech, USA)
of FH purified from human plasma was used. FHL-1 (402Y) and
FH fragments FH6–8, FH19–20 and FH8–15 were produced as
secreted proteins in Pichia pastoris as described previously (Schmidt
et al. 2008; Clark et al. 2014). In brief, P. pastoris cells (strain
KM71H, Invitrogen) that had been stably transformed with the
expression cassette (pPICZαB, Invitrogen) containing the relevant
coding DNA were grown in a fermenter and protein expression was
induced by supplementation with methanol (according to standard
procedure described by the supplier’s manual and as published in
detail in Schmidt et al. (2011)). The recombinant proteins were puri-
fied by consecutive cation- and/or anion-exchange chromatography
steps. The construct FHL-1 (corresponding to FH1–7), FH6–8 and
FH19–20 are not glycosylated in P. pastoris, in contrast to FH8-15.
However, the N-linked glycans of FH8–15 were removed during
the purification process with the endoglycosidase Endo Hf (New
England Biolabs). Optionally a size-exclusion chromatography was
employed to further increase purity if necessary.
AP hemolytic assay
This assay is based on the findings that sialic acid moieties on
sheep erythrocytes are crucial to restrict the alternative comple-
ment pathway (Fearon 1978; Pangburn and Müller-Eberhard
1978; Michalek et al. 1988a). 1 mL of defibrinated sheep blood
(TCS Biosciences) was diluted with 10 mL precooled buffer
(20 mM HEPES, 145 mM NaCl, 0.1% (w/v) gelatin (from pork
skin, Fluka) and 10 mM EDTA, pH 7.3 at 25°C). The cell suspen-
sion was mixed gently and spun for 10 min at 500 × g, at 4°C.
The supernatant and a layer of leukocytes were aspirated off and
the procedure was repeated two more times with buffer and sub-
sequently three times with an identical buffer without EDTA but
with 5 mM MgCl2 and 5 mM EGTA (Mg-EGTA). 2.5 μL of the
concentrated cell suspension was then mixed with 20 μL of nor-
mal human serum and 1 μL of 100 mM Mg-EGTA. Recombinant
FH fragments (FH19–20, FH6–8 402Y or FH6–8 402 H) were
added from 30 μM stocks prepared in HEPES/NaCl buffer with-
out further supplements. Final recombinant protein concentra-
tions were 0.3 μM, 0.6 μM, 1.3 μM, 2.5 μM, 5.0 μM and 10 μM.
Individual reaction volumes were adjusted to 40 μL with HEPES/
NaCl buffer without supplements. Individual reactions were incu-
bated for 20 min at 37°C, stopped by addition of 150 μL cold buf-
fer without gelatin but with 10mM EDTA, and spun at 1500 × g for
5min at 4°C. A control experiment was conducted without
recombinant FH fragments and heat-inactivated human serum
(56°C for 30min). Hemolysis was determined as absorbance of the
supernatant at 415 nm (A415) and compared to the A415 value for
the same amount of cells lysed with distilled water. Four independ-
ent experiments were conducted and A415 values averaged for each
data point.
NMR spectroscopy
NMR spectra were recorded at 283 K using 3mm tubes (200 μL
sample volume) and a Bruker AVIII-600 spectrometer equipped
with a room temperature probe head and processed with TOPSPIN
3.0 (Bruker). Samples for STD NMR spectra with Neu5Ac-
containing glycans contained 2mM of each of the three glycans (3′
SL, 6′SL and the GD3 glycan) and varying concentrations (10 μM ±
2 μM) of either full-length FH (Complement Technology, Inc.),
recombinant FHL-1 μM, recombinant FH6–8 402Y, or recombinant
FH8–15. Proteins were buffer-exchanged prior to NMR experiments
in 10 kDa MWCO centrifugal concentrators to 20mM potassium
phosphate pH 7.4, 150mM NaCl in D2O. Individual glycans were
added to the protein samples from 40mM stock solutions prepared
in D2O. A sample with 2mM of each of the three glycans but with-
out protein was used to verify that no direct excitation of the gly-
cans took place during the on-resonance irradiation step of the STD
pulse program, and also to record a proton 1D reference spectrum
of the sugar mix.
Off- and on-resonance irradiation frequencies were set to
−30 ppm and 7.3 ppm, respectively. The irradiation power of the
selective pulses was 57Hz, the saturation time was 2 s, and the total
relaxation delay was 3 s. A 50ms continuous-wave spin-lock pulse
with a strength of 3.2 kHz was employed in order to suppress
residual protein signals. A total number of 512 scans were recorded.
A total of 12 k points were collected, and spectra were multiplied
with a Gaussian window function prior to Fourier transformation.
The sample with glycolyl-3′SL-ProN3 contained 8 μM FH and
2mM glycolyl-3′SL-ProN3 and was recorded at 288 K for technical
reasons with otherwise identical settings.
Enzymatic deglycosylation
FH at 1 μg/μL in PBS (Complement Technologies, Texas) was dena-
tured for 10min at 95°C with the NEB protein denaturation buffer
supplied with the NEB deglycosylation mix, and subsequently cen-
trifuged for 5 min at 16,900 ×g. One microgram of denatured FH
was then mixed 1:0.25 with 4-fold reducing SDS-PAGE buffer
(29% (v/v) glycerol, 290mM Tris pH 6.8, 1.5% (w/v) SDS, 12mM
EDTA, 3M 2-mercaptoethanol) and left to incubate at room tem-
perature for 10min while another μg was treated with PNGase F
(NEB, glycerol-free, from Elizabethkingia miricola) and 1 μg was
treated with the NEB deglycosylation mix (containing PNGase F
from Elizabethkingia miricola, O-glycosidase from Enterococcus
faecalis, α2-3,6,8,9 neuraminidase A from Arthrobacter ureafa-
ciens, β1-4 galactosidase S from Streptococcus pneumoniae, and
β-N-acetylhexosaminidasef from Streptomyces plicatus). The reac-
tions were left to incubate at 37°C for 4 h, centrifuged for 10 min
at 16,900 rpm (g), incubated with reducing SDS-PAGE buffer for
10 min at room temperature, centrifuged again and subsequently
subjected to SDS-PAGE. Bovine fetuin (which contains O- and
N-glycosylation) was used as a positive control for PNGase F and
the deglycosylation mix.
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N-glyan release and linkage-specific sialic acid
derivatisation
Five microgram of the protein was denatured with 10 μL 2%
sodium dodecyl sulfate (SDS; Merck, Darmstadt, Germany) by incu-
bation for 10min at 60°C. Subsequently the release step was per-
formed by adding 10 μL of a mixture containing 2% Nonidet P-40
(NP-40) and 1 U recombinant peptide-N-glycosidase F (PNGase F;
Roche Diagnostics, Mannheim, Germany) in 2.5× PBS, followed by
overnight incubation at 37°C. The released glycans were derivatized
by ethyl esterification as described by elsewhere (Reiding et al.
2014). Briefly, the derivatization reagent mixture contains 0.25M
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide ((EDC); Fluorochem,
Hadfield, UK) and 0.25M 1-hydroxybenzotriazole ((HOBt); Sigma-
Aldrich, Steinheim, Germany), in ethanol (Merck). Twomicroliter
of released N-glycans were added to 20 μL of derivatization reagent
and incubated 1 h at 37°C. Allowing to cool down to room tem-
perature, the derivatized glycans were purified by hydrophilic inter-
action chromatography (HILIC) using pipette tips filled with cotton
as stationary phase (Selman et al. 2011). Briefly, 20 μL of aceto-
nitrile ((ACN); Biosolve, Valkenswaard, The Netherlands) was
added to the reaction mixture. The cotton inserted tips were washed
with three-times 20 μL of MQ water and three-times 20 μL of 85%
ACN followed by sample loading by pipetting 20 times up and
down. Finally, cotton tips were washed by pipetting three-times
20 μL 85% ACN containing 1% trifluoroacetic acid ((TFA); Merck)
and three-times 20 μL 85% ACN prior to the elution of the deriva-
tized glycan sample using 10 μL MQ.
MALDI-TOF-MS-(/MS) analysis of released N-glycans
Two microliter of purified derivatized glycans were spotted on a
MTP AnchorChip 800/384 TF MALDI target plate (Bruker
Daltonics) together with 1 μL of matrix (5 mg/mL super-DHB,
1mM NaOH in 50% ACN) and left to dry at room temperature.
Mass spectrometry was performed in reflectron positive mode on an
UltrafleXtreme mass spectrometer with a Smartbeam-II laser
(Bruker Daltonics) controlled by flexControl 3.4 (Build 135). Within
a window of m/z 1000–5000, spectra were recorded with 10,000
laser shots at a frequency of 1000Hz, employing a full sample ran-
dom walking pattern of 100 shots per raster spot. Tandem mass
spectrometry (MALDI-TOF/TOF-MS/MS) was performed on the
most abundant peaks via laser-induced dissociation to confirm gly-
can composition (data not shown).
Data analysis of released N-glycans
For relative quantification and quality control of the spectra, the
raw spectra were exported from flexAnalysis 3.4 (Build 76; Bruker
Daltonics) as.txt file (x,y), and further processed by MassyTools
(version 0.1.8.0) (Jansen et al. 2015). Internal calibration based on a
predefined list of analytes was applied, and 15 visually detected gly-
can compositions were extracted by integrating the areas of 95% of
the theoretical isotopic envelope and subtracting from these the
background found within a window of 20m/z. The areas were nor-
malized to the sum of all areas, and derived traits were calculated
based on the compositional features. Analyses were performed in
duplicate.
Supplementary data
Supplementary data is available at GLYCOBIOLOGY online.
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